Jan 29, 2024, 10:53
Paolo Tarantino: The highly debated results of PALOMA2 now published on JCO
Paolo Tarantino, Medical Oncologist, PhD Università degli Studi di Milano, Research Dana-Farber Cancer Institute, Harvard University, shared a post on X/Twitter:
“The highly debated results of PALOMA2 now published on JCO: the addition of palbociclib to 1L letrozole did not improve OS in HR+ MBC. The reason for the discrepancy with ribociclib and abemaciclib data remains unclear. Ultimately led to a reduction in the use of palbociclib.”
View additional information.
Source: Paolo Tarantino/X